SCHEMBL1721063

SCHEMBL1721063

N[C@H]1CC[C@@H](c2ccccn2)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
MAPT P10636 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42
OPRM1 P35372 1/20 0.41
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
OPRL1 P41146 1/20 0.41
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
KDM4E B2RXH2 2/20 0.37
TRPV1 Q8NER1 2/20 0.37
LMNA P02545 1/20 0.37
CYP1A2 P05177 1/20 0.37
POLB P06746 1/20 0.37
CCR1 P32246 1/20 0.37
CCR5 P51681 1/20 0.37
CCR8 P51685 1/20 0.37
METAP1 P53582 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1721104 1.00 ALDH1A1 (0.42) ALDH1A1MAPTNPC1RAB9AKMT2A
SCHEMBL1721059 1.00 ALDH1A1 (0.42) ALDH1A1MAPTNPC1RAB9AKMT2A
SCHEMBL1721107 1.00 ALDH1A1 (0.42) ALDH1A1MAPTNPC1RAB9AKMT2A
SCHEMBL1721060 1.00 ALDH1A1 (0.42) ALDH1A1MAPTNPC1RAB9AKMT2A
SCHEMBL14619610 0.89 ALDH1A1 (0.44) ALDH1A1MAPTNPC1RAB9AKMT2A
SCHEMBL9999607 0.89 ALDH1A1 (0.44) ALDH1A1MAPTNPC1RAB9AKMT2A
SCHEMBL659325 0.82 KDM4E (0.48) ALDH1A1MAPTNPC1RAB9AKMT2A
SCHEMBL900225 0.82
SCHEMBL29448519 0.82
SCHEMBL7849318 0.78 ALDH1A1 (0.41) ALDH1A1MAPTNPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406266-B1 7-CYCLOALKYLAMINOQUINOLONES AS GSK-3 INHIBITORS KYORIN SEIYAKU KK (JP) 2013-12-25 EP disclosed
EP-2406266-A1 7-CYCLOALKYLAMINOQUINOLONES AS GSK-3 INHIBITORS Kyorin Pharmaceutical Co., Ltd. (JP) 2012-01-18 EP disclosed
US-8071591-B2 7-cycloalkylaminoquinolones as GSK-3 inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-12-06 US disclosed
WO-2010104205-A1 7-CYCLOALKYLAMINOQUINOLONES AS GSK-3 INHIBITORS KYORIN PHARMACEUTICAL CO., LTD. (JP) 2010-09-16 WO disclosed
US-20100234367-A1 7-CYCLOALKYLAMINOQUINOLONES AS GSK-3 INHIBITORS Kyorin Pharmaceuticals Co. Ltd 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234367-A1 7-CYCLOALKYLAMINOQUINOLONES AS GSK-3 INHIBITORS GSK3B, GSK3A, GSKIP ALDH1A1 3225/4885MAPT 716/4885NPC1 318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.